Radian (RDN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RDN stock is poised to gain from a growing insurance portfolio, declining claims, solid capital strength, and effective capital deployment.

Discovery reaction monitoring for Pharma: The need to speed the drug discovery and development process has never been greater ...

Fintel reports that on May 23, 2025, Compass Point downgraded their outlook for Radian Group (NYSE:RDN) from Buy to Neutral.

No, not those sorts of drugs, the kinds that could save your life.

By units, 1.068 million were produced in the period ended March 31, compared with 1.076 million for the same three months in 2024. "MI management teams across the industry continue to stress that ...

With all the materials needed in hand, it is time to get on with the build. The first thing to do is print out the 3D part you’ll need for this build. We have included the models above, but ...